M11 - NALOXONE (NARCAN)

<table>
<thead>
<tr>
<th>Date</th>
<th>Provider</th>
<th>Age Group</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>2020-05-25</td>
<td>EMR</td>
<td>All ages</td>
<td>5 years &amp; over → 2 mg</td>
</tr>
<tr>
<td></td>
<td>PCP</td>
<td></td>
<td>12 months up to 5 years → 1 mg</td>
</tr>
<tr>
<td></td>
<td>ICP</td>
<td></td>
<td>72 hours up to 12 months → 0.1 mg/kg (single max dose = 1 mg)</td>
</tr>
<tr>
<td></td>
<td>ACP</td>
<td></td>
<td><strong>REPEAT DOSING:</strong> 4</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Every 3 to 5 minutes as required</td>
</tr>
</tbody>
</table>

INTRANASAL 2
(EMR & ABOVE)

DOSE:
- 5 years & over → 2 mg
- 12 months up to 5 years → 1 mg
- 72 hours up to 12 months → 0.1 mg/kg (single max dose = 1 mg)

REPEAT DOSING: 4
- Every 3 to 5 minutes as required

INTRANASAL 3
(PCP & ABOVE)

DOSE:
- 5 years & older → 2 mg
- 12 months up to 5 years → 1 mg
- 72 hours up to 12 months → 0.1 mg/kg (single max dose = 1 mg)

REPEAT DOSING: 4
- Every 10 minutes as required

INTRAVENOUS / INTRAOSSEOUS
(PCP & ABOVE)

DOSE: 5
- 5 years & older → 2 mg
- 12 months up to 5 years → 1 mg
- 72 hours up to 12 months → 0.1 mg/kg (single max dose = 1 mg)

REPEAT DOSING: 4
- Every 3 to 5 minutes as required
### INDICATIONS:
- Respiratory depression due to known or suspected opioid ingestion or administration

### NOTES:
1. With known or suspected opioid toxicity, management of the airway and breathing takes priority over naloxone administration.
2. Do not administer by intranasal route during the COVID-19 pandemic.
3. Consider alternate route if patient has a known bleeding disorder or is on anticoagulant, or administer with caution.
4. For known or suspected high potency opioids (eg. fentanyl, carfentanil), multiple doses may be required.
5. In chronic opioid users, providers at the ICP level and above may consider titrating smaller doses (0.1 mg) of IV naloxone to achieve and maintain adequate ventilations, without precipitating agitation or acute withdrawal.

<table>
<thead>
<tr>
<th>APPROVED BY:</th>
<th>abile M. Herd, Medical Director - Provincial EMS/PT</th>
<th>2020-05-25</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anita Vermaak, Associate Medical Director – Provincial EMS/PT</td>
<td>2020-05-26</td>
<td></td>
</tr>
</tbody>
</table>

### CHANGE TRACKING:

**2020-05-25:**
- Correction for intranasal dose & IV administration also within PCP scope
- All dosing simplified for ease of recall

**2020-05-01:**
- IM administration now in scope for PCP

**2017-06-27:**
- Original version